System for evaluating curative effect of treating liver cancer by combining HDRBT with thermal ablation in multi-mode radiomics

By constructing a three-dimensional visualization model and screening differential proteins using multimodal radiomics technology, the combined treatment regimen of HDRBT and thermal ablation was optimized, solving the problems of incomplete ablation and recurrence in the treatment of hepatocellular carcinoma, achieving precision treatment and safety assessment, and improving the efficacy and safety of liver cancer treatment.

CN120853956AActive Publication Date: 2025-10-28ZHEJIANG CANCER HOSPITAL

Patent Information

Application Number
CN202511360445.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-23
Publication Date
2025-10-28
Estimated Expiration
2045-09-23

AI Technical Summary

Technical Problem

Among existing treatments for hepatocellular carcinoma, thermal ablation alone is prone to incomplete ablation, leading to recurrence and metastasis. There is limited basic research on the use of HDRBT alone, and there is a lack of effective three-dimensional visualization tools to optimize preoperative planning, intraoperative guidance, and postoperative efficacy evaluation of combined therapy, which limits the precision and effectiveness of combined therapy.

Method used

A HepG2 nude mouse orthotopic hepatocellular carcinoma model was constructed. A three-dimensional visualization model was created by combining multimodal radiomics technology with image segmentation algorithms. The HDRBT catheter insertion path and thermal ablation electrode position were optimized. Differential proteins were screened by mass spectrometry, and their expression levels were verified by RT-PCR and immunohistochemistry. The molecular mechanism of combination therapy was revealed, and the dose distribution and treatment sequence were optimized to achieve individualized treatment plans.

Benefits of technology

It significantly improves the precision and effectiveness of combined treatment for liver cancer, reduces tumor recurrence rate and the risk of damage to adjacent tissues, provides molecular-level efficacy prediction and safety assessment, and enhances the feasibility and safety of treatment plans.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120853956A_ABST
    Figure CN120853956A_ABST
Patent Text Reader

Abstract

The invention discloses a curative effect evaluation system for treating liver cancer by combining HDRBT with thermal ablation in multi-modal radiomics, and relates to the field of liver cancer treatment, and the system comprises a multi-modal image data acquisition module which is used for collecting multi-modal image data; the three-dimensional visual model construction module is used for reconstructing a three-dimensional structure of liver tumors, peripheral blood vessels and bile ducts through an image segmentation algorithm, and generating a visual model by fusing radiomics characteristics; the combined treatment plan generation module is used for integrating the dosimetry parameters of the HDRBT and the process parameters of the thermal ablation, optimizing a catheter implanting path, the position of a thermal ablation electrode and a treatment sequence, and generating a combined treatment scheme; and the curative effect evaluation module is used for quantitatively analyzing tumor volume change, ablation boundary integrity and residual tumor activity through accurate registration of multi-modal images before and after treatment. According to the scheme, the problems of incomplete thermal ablation and high recurrence rate of hepatocellular carcinoma can be solved, and full-chain technical support is provided for clinical precise application.
Need to check novelty before this filing date? Find Prior Art

Description

Background Technology

[0001] This invention relates to the field of liver cancer treatment, and in particular to a multimodal radiomics HDRBT combined with thermal ablation therapy for liver cancer efficacy evaluation system.

[0002] Hepatocellular carcinoma (HCC) is a highly malignant digestive system tumor with extremely poor prognosis worldwide. It ranks fifth in incidence and third in mortality among malignant tumors, with Chinese patients accounting for approximately 50% of global cases. While surgical resection is the preferred treatment for HCC, only a small number of patients are eligible due to factors such as complex tumor location, insufficient liver function reserve, or disease progression. Thermal ablation, as a minimally invasive treatment, can achieve survival rates similar to surgical resection in small HCCs. However, for large tumors or lesions near important structures such as blood vessels and bile ducts, incomplete ablation is easily caused by thermal sedimentation, leading to tumor recurrence and metastasis. High-dose-rate brachytherapy (HDRBT), by directly implanting a radiation source into the tumor tissue, can precisely deliver a high radiation dose to the tumor area while reducing damage to surrounding normal tissues, providing a potential strategy to compensate for the limitations of thermal ablation. However, the synergistic mechanism of combined HDRBT and thermal ablation in the treatment of HCC is not yet clear, and the lack of effective three-dimensional visualization tools to optimize preoperative planning, intraoperative guidance, and postoperative efficacy assessment of combined treatment limits the precision and effectiveness of the combined therapy.

[0003] In existing treatments for hepatocellular carcinoma (HCC), thermal ablation alone is prone to incomplete ablation due to tumor characteristics, leading to recurrence and metastasis. Basic research on the application of HDRBT alone in HCC is limited, and the parameter optimization and synergistic mechanisms of its combination with thermal ablation have not been systematically explored. Traditional two-dimensional imaging assessments cannot accurately reflect the three-dimensional spatial relationship between the tumor and surrounding anatomical structures, failing to provide precise guidance for needle placement, dose distribution, and safety boundaries in combined therapy. Furthermore, the lack of research on molecular mechanisms such as differentially expressed proteins makes it impossible to effectively predict the efficacy of combined therapy and guide personalized treatment, thus limiting its clinical translation. Therefore, based on the above challenges, this invention proposes a multimodal radiomics-based HDRBT combined with thermal ablation efficacy evaluation system for HCC. Summary of the Invention

[0004] Purpose of the Invention To address the aforementioned issues, the present invention aims to provide a multimodal radiomics-based HDRBT combined with thermal ablation therapy for hepatocellular carcinoma (HCC) efficacy evaluation system. This system establishes a HepG2 nude mouse orthotopic HCC model, tests the feasibility of three-dimensional visualization and preoperative planning models, evaluates the effectiveness and safety of HDRBT combined with thermal ablation therapy for HCC, and screens differentially expressed proteins to reveal their mechanisms of action. This lays a theoretical and technical foundation for precise clinical planning, efficacy prediction, and mechanistic research in combined therapy for HCC.

[0005] Technical solution To achieve the above objectives, this invention provides a multimodal radiomics-based HDRBT combined with thermal ablation therapy for liver cancer efficacy evaluation system. This system constructs a HepG2 nude mouse orthotopic liver cancer model, monitors tumor growth using high-frequency ultrasound and CT scans, and utilizes multimodal imaging combined with image segmentation algorithms to create a three-dimensional visualization model, optimizing the HDRBT catheter insertion path and thermal ablation electrode position. Tumor inhibition rate is calculated using tumor growth curves and tumor weight, and tumor inactivation is assessed using contrast-enhanced ultrasound. Treatment safety is evaluated using liver and kidney function blood indicators and HE staining. The core mechanism of this system lies in using mass spectrometry to screen differentially expressed proteins between the combined and incomplete ablation groups, verifying their expression levels using RT-PCR and immunohistochemistry, and analyzing the correlation between differentially expressed proteins and hepatocellular carcinoma prognosis using bioinformatics tools, thus revealing the molecular mechanism of HDRBT combined with thermal ablation.

[0006] In a first aspect, the present invention provides a multimodal radiomics-based HDRBT combined with thermal ablation therapy for liver cancer efficacy evaluation system, comprising: The multimodal image data acquisition module is used to acquire multimodal image data from ultrasound, CT, and MRI, where ultrasound provides real-time guidance information, and CT and MRI provide high-resolution anatomical structure information. The 3D visualization model construction module, based on the multimodal image data, reconstructs the 3D structure of liver tumors, surrounding blood vessels and bile ducts through image segmentation algorithms, and integrates the radiomics features of tumor margins, tissue density and blood vessel distribution to generate an interactive 3D visualization model. The combined treatment plan generation module, based on the three-dimensional visualization model, integrates the dosimetric parameters of HDRBT with the process parameters of thermal ablation, optimizes the catheter insertion path, thermal ablation electrode position and treatment sequence, and generates an individualized combined treatment plan. The efficacy assessment module uses precise registration of multimodal images before and after treatment to quantitatively analyze changes in tumor volume, the integrity of ablation boundaries, and residual tumor activity. The safety assessment module integrates liver and kidney function indicators, pathological HE staining results, and adverse reaction records to evaluate the safety of combination therapy.

[0007] Furthermore, the multimodal image data acquisition module integrates real-time ultrasound imaging with high-resolution imaging from CT and MRI using magnetic positioning technology to achieve dynamic image alignment.

[0008] Furthermore, the three-dimensional visualization model construction module uses a deep convolutional neural network to segment liver tumors and blood vessels, and optimizes the segmentation results through a variational energy function.

[0009] Furthermore, the combined treatment plan generation module is based on a three-dimensional visualization model and uses a topology optimization algorithm to optimize the catheter insertion path.

[0010] Furthermore, the image segmentation algorithm is preferably a combination of convolutional neural networks and a region competition model.

[0011] Furthermore, the combined treatment plan generation module includes an HDRBT synergistic dose optimization model for thermal ablation of residual tumor, which dynamically adjusts the HDRBT edge dose based on the residual tumor volume ratio after thermal ablation.

[0012] Based on the radiosensitizing effect of residual tumor after thermal ablation, the proportion of residual tumor volume is used as the core parameter for dose adjustment to dynamically optimize the edge and center dose distribution of HDRBT. This significantly enhances the clearance efficacy of residual lesions and, through three-dimensional visualization, constrains the dose exposure to normal tissues, substantially reducing the incidence of liver and kidney damage and biliary complications. Furthermore, this model shows a biological correlation with the expression level of the differentially expressed protein G6PD, providing molecular-level closed-loop validation for efficacy prediction.

[0013] Furthermore, the dosimetric parameters of the HDRBT include edge dose, center dose, residence time, etc., and the process parameters of the thermal ablation include power, time, ablation range, etc.

[0014] Furthermore, the efficacy assessment module analyzes the residual tumor activity through the dynamic enhancement curve characteristics of ultrasound contrast imaging to determine the completeness of tumor ablation.

[0015] Furthermore, the safety assessment module uses the analytic hierarchy process to quantify liver and kidney function indicators, pathological results, and adverse reactions into safety scores to assess the safety level.

[0016] Furthermore, the liver and kidney function indicators include ALT, AST, bilirubin, etc., and the pathological HE staining results include the degree of hepatocellular necrosis, inflammatory infiltration, etc.

[0017] Secondly, the present invention also provides a catheter parameter generation system for combined liver cancer treatment, comprising: The biomarker association module is used to receive detection data from tumor tissue samples, extract the expression levels of biomarkers related to residual tumor volume, and establish a correlation model between the expression level of the biomarker and the proportion of residual tumor volume. The dynamic dose control module dynamically corrects the HDRBT edge dose based on the residual tumor volume ratio output by the correlation model and the three-dimensional topology modeling unit. The catheter parameter generation module is used to generate manufacturing instructions for catheter length, radiation source residence position and residence time based on the corrected dose parameters and the catheter layout path of the 3D model, and output them to the 3D printing equipment.

[0018] Furthermore, the biomarker association module includes a verification unit for verifying the expression level of the biomarker using molecular biology methods.

[0019] Thirdly, the present invention also provides a method for screening differentially expressed proteins in HDRBT combined with thermal ablation therapy for liver cancer, the method being based on the aforementioned system and comprising: Tumor tissue samples were collected from the combined treatment group, the thermal ablation group, the HDRBT group, and the control group. Mass spectrometry was used to analyze the sample proteome and screen for differentially expressed proteins. Verify the expression levels of differentially expressed proteins using molecular biology methods; We used bioinformatics tools to analyze the correlation between differentially expressed proteins and the prognosis of hepatocellular carcinoma.

[0020] This invention integrates multimodal imaging data from ultrasound, CT, and MRI, and reconstructs a precise three-dimensional model of liver cancer lesions, blood vessels, and the biliary system using a dynamic weighted fusion algorithm, overcoming the limitations of single-modal imaging. Based on the three-dimensional model, it collaboratively optimizes the placement of thermal ablation electrodes and HDRBT catheters, and establishes a dynamic adjustment model of radiation dose driven by residual tumor volume to quantify the radiosensitization effect after thermal ablation. It quantitatively analyzes changes in tumor volume, ablation boundary integrity, and residual tumor activity through multimodal image registration before and after treatment, and constructs a hierarchical analysis safety scoring model by combining liver and kidney function indicators and pathological HE staining. Furthermore, it screens differentially expressed proteins using mass spectrometry to verify their value as predictive biomarkers for combined therapy efficacy, revealing the synergistic mechanism by which the G6PD-STAT3 signaling axis regulates the epithelial-mesenchymal transition process.

[0021] This approach significantly reduces 3D reconstruction errors, improves catheter insertion and positioning accuracy, and increases ablation boundary coverage to over 95%, ensuring complete coverage of the tumor and safety boundaries, thus resolving the spatial deviation problem of traditional 2D planning. The residual tumor volume and local recurrence rate in the combined treatment group are significantly lower than those of single therapy, with a 46.3% increase in tumor inhibition rate. Mechanistically, this is achieved by inhibiting epithelial-mesenchymal transition through low G6PD expression, enhancing the clearance efficacy of HDRBT for residual lesions. Based on 3D model-based catheter path topology optimization and dose constraint, the degree of liver function damage is reduced by 40.7%, and the incidence of biliary complications is reduced to zero, achieving a balance between efficacy and toxicity. G6PD expression level, as a biomarker, can predict patient efficacy, providing a molecular basis for personalized treatment. This approach systematically addresses the problems of incomplete thermal ablation and high recurrence rates in hepatocellular carcinoma, providing full-chain technical support for the precise clinical application of HDRBT combined with thermal ablation.

[0022] Beneficial effects By implementing the multimodal radiomics HDRBT combined with thermal ablation therapy efficacy evaluation system for liver cancer provided by the present invention, the following technical effects are achieved: (1) By integrating multi-dimensional radiomics features such as tumor texture, morphology, and enhancement, a dynamic and interactive three-dimensional treatment model is constructed, overcoming the visual limitations of traditional two-dimensional planning. Its core lies in achieving global optimization of treatment parameters, intelligently avoiding key structures based on the topological relationship between blood vessels and bile ducts, and simultaneously optimizing the spatial arrangement sequence of HDRBT catheter placement and thermal ablation electrodes to maximize the synergistic effect of combined treatment. This planning system can significantly improve the executability of treatment plans, reduce the frequency of real-time adjustments during surgery, and lower the risk of accidental damage to adjacent tissues.

[0023] (2) By screening and verifying the negative correlation between the expression level of the differentially expressed protein G6PD and treatment response, G6PD was established as a prognostic indicator for HDRBT combined with thermal ablation. This revealed the molecular mechanism of the combined therapy. By detecting the expression level of G6PD preoperatively, the sensitivity of patients to the combined therapy can be predicted, guiding the selection of individualized treatment plans. Bioinformatics analysis further confirmed the significant association between this biomarker and patient survival, providing molecular target support for precision medicine.

[0024] (3) By dynamically fusing high-resolution anatomical information from CT with real-time functional information from ultrasound, the accuracy of three-dimensional reconstruction of liver cancer and surrounding vascular and bile duct structures is significantly improved. The generated fused images have significant advantages in tumor boundary restoration and spatial relationship consistency, overcoming the inherent limitations of single-modal imaging. This provides a reliable guarantee for the spatial positioning accuracy of catheter insertion and thermal ablation electrodes, fundamentally improving the matching degree between treatment path planning and intraoperative navigation, thereby optimizing the coverage integrity of the safety boundary and reducing the risk of secondary intervention due to image deviation.

[0025] (4) Based on the radiosensitizing effect of residual tumor after thermal ablation, the proportion of residual tumor volume is used as the core parameter for dose adjustment to dynamically optimize the edge and center dose distribution of HDRBT. On the one hand, this significantly enhances the clearance efficacy of residual lesions; on the other hand, it constrains the dose exposure of normal tissues through three-dimensional visualization, fundamentally reducing the incidence of liver and kidney dysfunction and biliary complications. In addition, this model shows a biological correlation with the expression level of the differentially expressed protein G6PD, providing molecular-level closed-loop validation for efficacy prediction. Attached Figure Description

[0026] To make the above-mentioned multimodal radiomics HDRBT combined with thermal ablation therapy for liver cancer efficacy evaluation system of the present invention more obvious and easy to understand, the accompanying drawings used in the specific embodiments of the present invention will be briefly introduced below. Obviously, the accompanying drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0027] Figure 1 This is a flowchart illustrating the construction process of a 3D visualization model. Figure 2 This graph shows the tumor growth curves in nude mice treated with microwave ablation and radiofrequency ablation for subcutaneous tumors. Figure 3 This is a flowchart illustrating the experimental evaluation of the effectiveness of ultrasound-guided HDRBT combined with thermal ablation in the treatment of hepatocellular carcinoma. Figure 4 The graph shows the tumor growth curve, body weight change curve, and tumor weight difference of nude mice. Figure 5 This graph represents the evaluation of the therapeutic effect of HDRBT combined with thermal ablation observed by ultrasound contrast imaging. Figure 6 A graph showing the comparison of blood indicators of liver and kidney function among different groups; Figure 7 A graph showing the comparison of blood indicators of liver and kidney function among different groups; Figure 8 This shows the HE staining diagrams for each group; Figure 9 A graph showing the comparison of immunohistochemical indicators among groups; Figure 10 Survival curves representing different G6PD expression groups; Figure 11 Survival curves for different G6PD expression groups. Detailed Implementation

[0028] It should be understood that none of the technical solutions claimed in this invention relate to the diagnosis and treatment of diseases.

[0029] To facilitate understanding of the embodiments of the present invention, the abbreviations and key terms that may be involved in the embodiments of the present invention will first be explained or defined. For undefined abbreviations or key terms, they are all conventionally understood by those skilled in the art.

[0030] HDRBT: High Dose Rate Brachytherapy; G6PD: glucose-6-phosphate dehydrogenase; PCDA: Programmed cell death-associated antigen; TUNEL: Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling method; HE staining: hematoxylin-eosin staining; EMT: Epithelial-mesenchymal transition; iMWA: Incomplete microwave ablation; cMWA: Complete microwave ablation; HDRBT+iMWA: Combined treatment group; STAT3: Signal transduction factor; Snail: an EMT-regulated transcription factor; OS: Total Lifetime; RT-PCR: Reverse transcription polymerase chain reaction; SDS In-solution digestion: a sample preprocessing technique for proteomics. CEUS: Contrast-enhanced ultrasound; IHC: Immunohistochemistry; The present invention will now be described in detail.

[0031] Example 1: When performing thermal ablation on large tumors, the advantages of 3D visualization software in three-dimensional display and precise measurement become apparent. 3D planning allows for a more comprehensive estimation of the ablation treatment difficulty and a more accurate prediction of the treatment extent, leading to a greater likelihood of thorough treatment during ablation. Previous studies on thermal ablation of hepatocellular carcinoma generally set the safe ablation boundary or resection margin width at 5-10 mm. 3D visualization-based efficacy evaluation methods can quantitatively evaluate the ablation boundary, offering superior comprehensiveness and accuracy compared to two-dimensional imaging-based methods.

[0032] The creation process of the HDRBT 3D visualization animal model is as follows: Figure 1 As shown.

[0033] The experimental animals included 40 male nude mice, aged 4-6 weeks, SPF grade, which were housed in a clean cabinet in the animal room.

[0034] HepG2 cells were routinely cultured and passaged to establish a subcutaneous tumor-bearing model in nude mice. The mice were fed for 28 days, and the tumors were harvested for in situ liver implantation. The skin was disinfected, the tumor was removed, and the mice were repeatedly rinsed 2-3 times with sterile ice-cold saline. The tumor fragments were then cut into 2mm diameter pieces for implantation. The tumor tissue was implanted into the nude mouse liver within 30 minutes of removal. The mice were placed in a supine position. The surgical field skin was disinfected twice with 0.5% iodine solution. An 8mm oblique incision was made below the left costal margin, and the abdominal wall was opened to expose the liver. A tunnel was created along the liver capsule using pointed forceps, and the tumor tissue fragment was implanted. The liver resection margin was sutured with 8-0 atraumatic surgical sutures to fix the tumor fragment. The liver was gently returned to the abdominal cavity, and the abdominal wall was closed with 6-0 sutures. The entire procedure was performed in a sterile laminar flow hood. After anesthesia recovery, the mice were returned to their cages. Postoperative antibiotics were not used, and the mice were allowed free access to food.

[0035] The volume of the tumor to be transplanted is approximately Tumor-forming nude mice were randomly divided into four groups: the combined group, the HDRBT group, the thermal ablation group, and the control group, with 10 nude mice in each group.

[0036] The process of exploring HDRBT conditions in animal models is described below.

[0037] The 3D visualization software system requires pre-treatment CT or MRI scan data, i.e., continuous two-dimensional tomographic images of the lesion area, in DICOM format. The DICOM data is imported into the software system, and a suitable scan sequence is selected through the DICOM browser. After preprocessing the two-dimensional images, 3D modeling is performed to obtain three-dimensional images and measurement data of the lesion and related anatomical structures. Before treatment, surgical planning is performed through interactive operation of the software, designing the optimal needle insertion diameter and needle placement plan. During treatment, magnetically located medical image fusion and surgical navigation are performed. After treatment, efficacy is evaluated through precise registration of the pre- and post-treatment 3D medical image data.

[0038] First, conditions are explored to determine the number of catheters, dosage, and number of irradiations for HDRBT. Under ultrasound guidance, the insertion direction, depth, and number of catheters are determined based on the tumor location, and the catheters are securely fixed to prevent bleeding. Since ultrasound provides two-dimensional images, the ultrasound probe is rotated 90 degrees at each insertion plane to obtain a three-dimensional image of the same cross-section, ensuring accurate placement of each delivery catheter. During catheter placement, the delivery catheters should be parallel and penetrate the tumor. Based on the desired dose to the tumor periphery, the location and duration of each residence point are calculated and determined using an interstitial therapy planning system.

[0039] For tumor implantation radiotherapy, the marginal dose is controlled at 10 Gy, while the central dose can reach 250 Gy. Treatment lasted 32 seconds. Studies have shown that HDRBT has good efficacy and safety in treating nude mice with subcutaneous tumors.

[0040] The process of exploring the conditions for thermal ablation in animal models is described below.

[0041] After drug anesthesia, thermal ablation therapy was performed. The surgical field was routinely disinfected and draped. The skin at the tumor site was cut open. Careful operation was taken during the procedure to avoid damaging the tumor. The tumor was exposed, and the radiofrequency needle was inserted to a depth of about 0.5 cm. The radiofrequency time was 30 seconds and the power was 10W to perform incomplete ablation of the tumor lesion.

[0042] Microwave ablation and radiofrequency ablation were compared in animal models. Based on the incomplete ablation power and time, changes in body weight and tumor size in tumor-bearing nude mice were observed over 7 days. The tumor growth curves of microwave ablation and radiofrequency ablation in subcutaneous tumor-bearing nude mice are shown below. Figure 2 As shown, the results indicate that nude mice do not tolerate radiofrequency ablation as well as microwave ablation, even though microwave ablation is clinically considered to have a wider treatment range.

[0043] Example 2: The evaluation process for the efficacy of ultrasound-guided HDRBT combined with thermal ablation in the treatment of hepatocellular carcinoma is as follows.

[0044] A subcutaneous mouse model of primary liver cancer was established. Under ultrasound guidance, percutaneous needle insertion was performed, followed by brachytherapy. The thermal ablation group underwent ultrasound-guided needle insertion and thermal ablation therapy. The combined group received thermal ablation followed by HDRBT. The negative control group only underwent tumor biopsy without any other treatment intervention. Figure 3 As shown. CT and contrast-enhanced ultrasound were used to observe tumor development and metastasis in nude mice, and three-dimensional reconstruction was performed to measure tumor volume, plot volume and time growth curves, calculate tumor formation rate, record survival time of tumor-bearing nude mice, and record adverse reactions in each group of nude mice.

[0045] To observe the growth of transplanted tumors in nude mice, growth curves of the transplanted tumors were plotted and tumor weight and tumor inhibition rate were calculated. The long diameter of the transplanted tumor was measured by ultrasound every two days. With short axis And calculate the tumor volume. The formula is Based on the calculated tumor volume, a growth curve of the xenograft tumor in nude mice was plotted. Blood was drawn to measure liver and kidney function before the nude mice were euthanized. The nude mice were euthanized after anesthesia with chloral hydrate, and the tumor tissue was dissected, photographed, and weighed. The average tumor weight and tumor weight inhibition rate were calculated. Tumor weight inhibition rate % = (tumor weight of blank control group - tumor weight of experimental group) / tumor weight of blank control group × 100%.

[0046] Nude mice were subjected to contrast-enhanced ultrasound examination via tail vein injection followed by administration of contrast agent by an experienced sonographer. After intraperitoneal anesthesia, a routine ultrasound scan was performed first to select the optimal scanning location and maximum cross-section of the tumor. The scan was then switched to contrast mode, and contrast agent was injected via tail vein bolus injection at a rate of 0.1 ml / kg body weight, followed by flushing with 2 ml of normal saline. Dynamic images were continuously acquired for 5 minutes and stored on the machine's hard drive.

[0047] The treatment efficacy assessment between each group is as follows.

[0048] The tumors were divided into five groups: Control, Incomplete ablation (iMWA), Complete ablation (cMWA), HDRBT (intercalation radiotherapy), and HDRBT+iMWA (combination group). Tumor growth curves (observed for 28 days post-treatment): From day 9 post-treatment, the HDRBT+iMWA group was significantly lower than the Control and HDRBT groups. From day 21 post-treatment, the HDRBT+iMWA group was significantly lower than the iMWA group, and the difference was statistically significant. Figure 4 As shown in D. There were no differences in tumor weight growth curves among the groups, as shown in Figure D. Figure 4 As shown in Figure E. The bar chart showing changes in tumor weight after dissection indicates a statistically significant difference between the HDRBT+iMWA group and the iMWA group.

[0049] Contrast-enhanced ultrasound can be used to observe the inactivation of subcutaneous tumors, such as... Figure 5 As shown.

[0050] Blood samples from nude mice in each group showed no statistically significant differences in liver and kidney function parameters between the HDRBT+iMWA group and the iMWA group. Figure 6 and Figure 7 As shown.

[0051] The trend charts of nude mouse body weight changes among the groups revealed that HDRBT combined with thermal ablation had a high safety profile. Furthermore, HE staining data from each group showed that both combined treatment and treatment alone were safe and effective. Figure 8 As shown.

[0052] Example 3: This embodiment explains the relevant mechanism of HDRBT combined with thermal ablation.

[0053] The process of screening differentially expressed proteins by mass spectrometry is shown below.

[0054] Sample processing followed the SDS in-solution digestion procedure: Add 40 μl of 50 mM ABC to an EP tube, followed by 10 μl of sample; then add 5 μl of 100 mM DTT to the EP tube and incubate at room temperature for 45 min; then add 5 μl of 100 mM IAA to the EP tube, protect from light, and incubate at room temperature for 45 min; then add 20 μl of 100 mM DTT to the EP tube and incubate at room temperature for 45 min; add 20 μl of 50 mM ABC to bring the total volume to 100 μl; add 2 μl of 0.1 μg / μL trypsin, followed by 4 μl of 10% SDC, mix thoroughly, and incubate overnight at 37°C; slowly add 5 μL of 10% TFA, mixing slowly, and incubate for 2 min to produce a white precipitate; centrifuge at 15000g for 30 min, carefully transfer the supernatant to a new tube; after desalting on a C18 column, vacuum dry, and add 30 μl of 0.1%... FA was reconstituted; after reconstitution, it was centrifuged at 15000g for 15 min, and approximately 25 μL of the supernatant was carefully collected and injected for mass spectrometry screening of differentially expressed proteins.

[0055] The following steps were performed according to the kit instructions: dewaxing, citric acid high-temperature retrieval, incubation with primary and secondary antibodies, and diaminobenzidine staining. Semi-quantitative immunohistochemical analysis was scored from 0 to 3 points based on cell staining depth and the number of positive cells. Light brown staining in the nucleus or cell membrane was 1 point, brown staining was 2 points, dark brown staining was 3 points, and no staining was 0 points. The percentage of positive cells in the microscopic field of view was <10% for 1 point, 10%-50% for 2 points, and >50% for 3 points. Based on the scores of these two indicators, a four-level classification was established: 0 for negative (-), 2-3 for weakly positive (+), 4 for positive (++), and 5-6 for strongly positive (+++).

[0056] Prepare a 6% gel on a 10% SDS-polyacrylamide gel, add 5 μl of sample, and electrophoresis for 90 min. Transfer the gel to a polyvinylidene fluoride (PVDF) membrane (PVDF membranes with a molecular weight greater than 130,000 require 150 min; membranes with a molecular weight between 40,000 and 130,000 require 90 min; membranes with a molecular weight less than 40,000 require 45–60 min), and block with 5% skim milk for 1 h. Cut the membrane with a molecular weight between 40,000 and 130,000 into two membranes with molecular weights between 75,000 and 130,000 and between 40,000 and 75,000. Dilute the protein antibody 1:1000 and the anti-GAPDH antibody 2:1000. Incubate overnight at 4°C, wash the membrane three times for 10 min each time with phosphate-Tween buffer, then add secondary antibody to the blocking buffer and incubate at room temperature for 2.5 h. Wash the membrane three times with phosphate-Tween buffer, 10 min each time. Develop color with chemiluminescent reagent.

[0057] After the experiment, the patients were anesthetized and euthanized. The tumors were dissected, their gross morphology was observed, and their weight was measured. Each tumor tissue was divided into two parts. One part was fixed and embedded for pathological examination, while the remaining tumor tissue was cryopreserved at -80°C. Immunohistochemistry and Western blot were used to detect EMT-related proteins such as G6PD, E-cadherin, N-cadherin, Vimentin, IL-6, STAT3, and Snail.

[0058] Mass spectrometry screening of tumor specimens from each group revealed that G6PD was one of the differentially expressed proteins. RT-PCR and immunohistochemical statistical results showed that the incomplete ablation group showed a high expression trend, which may be a potential target.

[0059] Immunohistochemical results among the specimens showed that G6PD expression was low in the HDRBT+iMWA group, significantly lower than in the iMWA group. Figure 9 As shown, the proliferation and apoptosis indicators are consistent with the treatment effect.

[0060] Using bioinformatics tools, differentially expressed G6PD was analyzed online according to tumor grade. Compared to normal specimens, G6PD expression was elevated in tumor specimens, and even higher expression was found in metastatic samples. Survival curves for different G6PD expression groups are shown below. Figure 10 and Figure 11 As shown in the figure, the correlation between G6PD levels and overall survival (OS) in hepatocellular carcinoma (HCC) patients was analyzed using a previously generated microarray dataset of 364 HCC patients. The results showed that high G6PD expression was associated with poor clinical prognosis in HCC patients (P<0.01). Elevated G6PD expression was also correlated with tumor stage; the higher the stage, the higher the G6PD expression.

[0061] In conclusion, G6PD plays an important role in promoting the progression of liver cancer.

[0062] Example 4: To address the complementarity of CT and ultrasound multimodal imaging, a dynamic weighted fusion algorithm is proposed. This algorithm dynamically adjusts the fusion weights of CT and ultrasound images by calculating their edge sharpness and tissue contrast, overcoming the limitations of single-modal imaging and achieving accurate three-dimensional reconstruction of liver cancer lesions and surrounding blood vessels and bile ducts.

[0063] The core logic of the algorithm is that images with high edge sharpness and good contrast are given higher weights to ensure that the fused images take into account both anatomical accuracy and real-time performance.

[0064] Enhanced CT images and real-time ultrasound images of liver cancer patients were acquired, covering the tumor and a 2cm radius around it. Gaussian filtering and Sobel edge enhancement were applied to the CT images, while speckle removal and histogram equalization were performed on the ultrasound images to improve contrast.

[0065] Edge sharpness is calculated using the average gradient magnitude, as shown in the formula:

[0066] In the formula, For edge sharpness; Image width; Image height; For pixels The gradient.

[0067] The formula for calculating the mean grayscale difference between the target area and the background area is:

[0068] In the formula, To enhance organizational contrast; This represents the number of pixels in the tumor region. The set of pixels in the target region; The grayscale value of the tumor pixel; This represents the average grayscale value of the background area.

[0069] By combining the edge sharpness and contrast of CT and ultrasound, dynamic fusion weights are calculated. :

[0070] In the formula, For edge sharpness of CT images; This refers to the edge contrast of CT images; The edge sharpness of the ultrasound image; The edge contrast of the ultrasound image; Used to prevent the denominator from being 0.

[0071] The merged pixel values ​​are:

[0072] In the formula, To merge the image in coordinates Pixel value at; The weights are dynamically fused, and their values ​​range from 0 to 1. These are the pixel values ​​of the CT image; The pixel value of the ultrasound image.

[0073] The fused 2D image sequence is imported into 3D visualization software, and the moving cube algorithm is used to reconstruct 3D models of liver cancer lesions, hepatic arteries, portal veins and bile ducts. It supports interactive operations such as rotation, scaling and sectioning, and outputs files that can be imported into treatment planning systems.

[0074] The algorithm's 3D reconstruction error was validated using 20 HepG2 nude mouse orthotopic liver cancer models. The error was significantly lower than that of single-modal CT reconstruction and ultrasound reconstruction. Based on this model, the HDRBT catheter insertion error was reduced to [amount missing]. The thermal ablation boundary coverage rate was increased to 95%. A clinical trial involving 10 liver cancer patients showed that the combined treatment group achieved a 92% complete tumor ablation rate and reduced the local recurrence rate to 8% within one year.

[0075] The results show that the algorithm significantly improves the accuracy and robustness of 3D reconstruction of liver cancer by dynamically weighted fusion of high-resolution anatomical information from CT and real-time guided information from ultrasound. The fused 3D model outperforms single-modal reconstruction techniques in terms of anatomical structure fidelity and real-time positioning consistency. The improved reconstruction accuracy directly optimizes the catheter insertion path and the positioning accuracy of the thermal ablation electrode, significantly improving the safety boundary coverage of combined therapy and reducing the need for intraoperative adjustments due to image registration deviations. Ultimately, the algorithm provides a reliable spatial benchmark for the collaborative planning of HDRBT and thermal ablation, and the combined therapy showed a systematic improvement in both the complete tumor ablation rate and local control rate in clinical trials.

[0076] Example 5: Thermal ablation causes thermal damage to tumor tissue, increasing the radiosensitivity of residual tumor cells. Simultaneously, the thermally coagulated layer creates a thermal protective effect, reducing radiation penetration into surrounding normal tissue. This model uses a three-dimensional visualization model to determine the ablation range and residual tumor volume. Combined with changes in radiosensitivity after thermal damage, it optimizes the edge and center doses of HDRBT, achieving a synergistic effect of thermal ablation reducing tumor burden and HDRBT clearing residual lesions.

[0077] Based on the three-dimensional visualization model of the aforementioned embodiment, the thermal ablation area is segmented using the enhanced CT image after thermal ablation, and the residual tumor area is segmented by identifying the enhanced region to calculate the total tumor volume.

[0078] The clone formation rate of residual tumor cells after thermal ablation was measured using 10 nude mice, and the radiosensitization ratio of thermally damaged cells to normal cells was found to be 1.5.

[0079] The optimized formula for the radiosensitization effect in the residual tumor area is as follows:

[0080] In the formula, This is the edge dose; This represents the percentage of residual tumor volume.

[0081] based on The optimized formula for the dose distribution characteristics of a radiation source is:

[0082] In the formula, The central dose.

[0083] The dose distribution of the radiation source follows the inverse square law, and the central dose being 25 times the peripheral dose is a specific parameter verified by Monte Carlo simulation.

[0084] The treatment planning system is used to simulate the dose distribution of HDRBT to ensure that: Dose coverage of the residual tumor area, with 95% of the residual tumor volume receiving ≥ marginal dose; Dose limits for surrounding normal tissues: dose ≤2Gy at 2cm outside the radiation source, maximum dose ≤5Gy in the bile duct.

[0085] In an experiment using 20 nude mice, the residual tumor volume in the combined treatment group was [missing data]. Significantly lower than the HDRBT group alone The tumor suppression rate reached 78%, significantly higher than the 55% in the HDRBT group alone. A clinical trial involving 10 patients showed that the combined treatment group had a 15% incidence of liver and kidney function impairment and a 0% incidence of bile duct injury. Furthermore, analysis of data from 364 liver cancer patients using bioinformatics tools revealed that the 1-year survival rate for patients with low G6PD expression treated with this model reached 85%, validating the model's predictive value for treatment efficacy.

[0086] The results showed that the model dynamically optimized the edge and center dose distribution of HDRBT by quantifying changes in the radiosensitivity of residual tumors after thermal ablation. This dosing strategy significantly enhanced the clearance efficiency of residual lesions; the residual tumor volume in the combination therapy group was significantly lower than that in the traditional fixed-dose group, and the tumor inhibition rate showed a substantial improvement. Simultaneously, the safe dose constraint based on the three-dimensional visualization model effectively reduced the radiotoxicity of normal tissues, manifested as a synergistic decrease in the degree of liver function damage and the incidence of biliary complications. Furthermore, the biological rationale for dose optimization was validated by the expression level of the differentially expressed protein G6PD, further confirming the clinical value of this model in predicting patient survival benefits and providing a theoretical framework for individualized combination therapy.

Claims

1. A multimodal radiomics-based HDRBT combined with thermal ablation therapy for liver cancer efficacy evaluation system, characterized in that, include: The multimodal image data acquisition module is used to collect multimodal image data and provide real-time guidance information and high-resolution anatomical structure information; The 3D visualization model construction module, based on the multimodal image data, reconstructs the 3D structure of liver tumors, surrounding blood vessels and bile ducts through image segmentation algorithms, and integrates the radiomics features of tumor margins, tissue density and blood vessel distribution to generate an interactive 3D visualization model. The combined treatment plan generation module, based on the three-dimensional visualization model, integrates the dosimetric parameters of HDRBT with the process parameters of thermal ablation, optimizes the catheter insertion path, thermal ablation electrode position and treatment sequence, and generates an individualized combined treatment plan. The efficacy assessment module uses precise registration of multimodal images before and after treatment to quantitatively analyze changes in tumor volume, the integrity of ablation boundaries, and residual tumor activity. The safety assessment module integrates liver and kidney function indicators, pathological HE staining results, and adverse reaction records to evaluate the safety of combination therapy.

2. The system according to claim 1, characterized in that: The multimodal image data acquisition module integrates real-time ultrasound imaging with high-resolution imaging from CT and MRI using magnetic positioning technology to achieve dynamic image alignment.

3. The system according to claim 1, characterized in that: The 3D visualization model construction module uses a deep convolutional neural network to segment liver tumors and blood vessels, and optimizes the segmentation results through a variational energy function.

4. The system according to claim 1, characterized in that: The combined treatment plan generation module is based on a three-dimensional visualization model and uses a topology optimization algorithm to optimize the catheter insertion path.

5. The system according to claim 4, characterized in that: The combined treatment plan generation module includes an HDRBT synergistic dose optimization model for thermal ablation of residual tumors. This model dynamically adjusts the HDRBT edge dose based on the proportion of residual tumor volume after thermal ablation.

6. The system according to claim 1, characterized in that: The efficacy assessment module analyzes the residual tumor activity and determines the completeness of tumor ablation by analyzing the dynamic enhancement curve characteristics of ultrasound contrast imaging.

7. The system according to claim 1, characterized in that: The safety assessment module uses the analytic hierarchy process to quantify liver and kidney function indicators, pathological results, and adverse reactions into safety scores to assess the safety level.

8. A catheter parameter generation system for combined liver cancer treatment, characterized in that, include: The biomarker association module is used to receive detection data from tumor tissue samples, extract the expression levels of biomarkers related to residual tumor volume, and establish a correlation model between the expression level of the biomarker and the proportion of residual tumor volume. The dynamic dose control module dynamically corrects the HDRBT edge dose based on the residual tumor volume ratio output by the correlation model and the three-dimensional topology modeling unit. The catheter parameter generation module is used to generate manufacturing instructions for catheter length, radiation source residence position and residence time based on the corrected dose parameters and the catheter layout path of the 3D model, and output them to the 3D printing equipment.

9. The system according to claim 8, characterized in that: The biomarker association module includes a verification unit for verifying the expression level of the biomarker using molecular biology methods.

10. A method for screening differentially expressed proteins in HDRBT combined with thermal ablation therapy for liver cancer, characterized in that: The method is based on the system according to any one of claims 1-9, comprising: Tumor tissue samples were collected from the combined treatment group, the thermal ablation group, the HDRBT group, and the control group. Mass spectrometry was used to analyze the sample proteome and screen for differentially expressed proteins. Verify the expression levels of differentially expressed proteins using molecular biology methods; We used bioinformatics tools to analyze the correlation between differentially expressed proteins and the prognosis of hepatocellular carcinoma.

Citation Information

Patent Citations

  • CT image-guided liver tumor thermal ablation needle location and navigation system

    CN105286988A

  • Liver tumor ablation postoperative three-dimensional space curative effect evaluation method and system

    CN110910406A

  • Liver 3D printing model construction method, system and equipment based on image data

    CN119068137A

  • Bone tumor thermal ablation treatment control device combined with machine learning

    CN120241227A

  • Hepatocellular carcinoma postoperative early-stage recurrence multi-modal prediction model based on enhanced CT image and construction method of hepatocellular carcinoma postoperative early-stage recurrence multi-modal prediction model

    CN120340854A

Cited By

  • Ultrahigh-strength self-focusing ultrasonic treatment system and use method

    CN121371534A